Cost Analysis of Complex Radiation Therapy for Patients With Head and Neck Cancer
- PMID: 27131080
- DOI: 10.1016/j.ijrobp.2016.02.013
Cost Analysis of Complex Radiation Therapy for Patients With Head and Neck Cancer
Abstract
Purpose: This cost analysis aimed to prospectively assess differences in costs between TomoTherapy and volumetric modulated arc therapy (VMAT) in patients with head and neck cancer.
Methods and materials: Economic data were gathered from a multicenter study. However, randomization was not possible due to the availability of equipment. Costs were calculated using the microcosting technique from the hospital's perspective (in 2013 euros), and the time horizon was radiation therapy. Only resources that entered the hospital production process and which were likely to vary between the strategies being compared were considered. Acute adverse events observed within the time horizon were also assessed.
Results: The cost analysis was based on a total of 173 patient treatments given between 2010 and 2012 in 14 French cancer centers: 73 patients were treated with TomoTherapy, 92 with VMAT RapidArc, and 8 with VMAT SmartArc. Estimated costs of SmartArc were removed from the comparison due to the small sample size. The mean ± SD cost per patient of the treatment planning phase was €314 (±€214) for TomoTherapy and €511 (±€590) for RapidArc. Mean costs ± SD per patient of irradiation reached €3144 (±€565) for TomoTherapy and €1350 (±€299) for RapidArc. The most sensitive parameter of irradiation was the annual operating time of accelerators. Ninety-five percent confidence intervals for the mean costs of irradiation were €3016 to €3272 for TomoTherapy and €1281 to €1408 for RapidArc. The number of acute adverse events during radiation therapy was not significantly different between strategies.
Conclusions: TomoTherapy appeared to be more expensive than RapidArc mainly due to the higher price of the accelerator, the higher costs of maintenance, and the longer duration of treatment sessions. Because strategies were not significantly different in clinical effect, RapidArc appeared to be the strategy to be recommended at this stage of knowledge.
Copyright © 2016 Elsevier Inc. All rights reserved.
Comment in
-
In Reply to Fodor and Di Muzio.Int J Radiat Oncol Biol Phys. 2016 Dec 1;96(5):1124-1126. doi: 10.1016/j.ijrobp.2016.09.003. Int J Radiat Oncol Biol Phys. 2016. PMID: 27869085 No abstract available.
-
In Regard to Perrier et al.Int J Radiat Oncol Biol Phys. 2016 Dec 1;96(5):1124. doi: 10.1016/j.ijrobp.2016.09.006. Int J Radiat Oncol Biol Phys. 2016. PMID: 27869086 No abstract available.
-
In Regard to Perrier et al.Int J Radiat Oncol Biol Phys. 2017 Jan 1;97(1):204-205. doi: 10.1016/j.ijrobp.2016.09.035. Int J Radiat Oncol Biol Phys. 2017. PMID: 27979448 No abstract available.
-
In Reply to Escande et al.Int J Radiat Oncol Biol Phys. 2017 Jan 1;97(1):205-208. doi: 10.1016/j.ijrobp.2016.09.032. Int J Radiat Oncol Biol Phys. 2017. PMID: 27979449 No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical